AmyriAD Therapeutics, a clinical-stage biopharmaceutical firm specializing in cognition-focused central nervous system (CNS) disorders, has announced the acquisition of Recognify Life Sciences. This strategic move is set to bolster AmyriAD’s therapeutic pipeline by absorbing Recognify’s lead clinical-stage asset, RL-007 (inidascamine).
The transaction marks a significant consolidation in the CNS pharmaceutical space. While AmyriAD will retain its flagship program, Ismidenon (AD-101), as its primary focus for Alzheimer’s disease, the addition of RL-007 provides the company with a diversified and expanded footprint in the treatment of cognitive impairment.
RL-007 is a pioneering, orally administered compound designed to improve cognitive function by modulating cholinergic, glutamatergic, and GABA-B receptor activity. By targeting these specific neural pathways, the drug aims to restore the delicate balance between excitatory and inhibitory signaling—a mechanism central to managing cognitive dysfunction across a spectrum of CNS disorders.
For AmyriAD, the acquisition of RL-007 is particularly valuable due to its existing clinical track record. The candidate has already demonstrated potential in addressing cognitive impairment associated with schizophrenia (CIAS), a challenging area with significant unmet medical needs. The company anticipates that this integration will allow for a robust dual-track development approach, leveraging the expertise of its CNS-focused team to advance both Ismidenon and RL-007 simultaneously.
“RL-007 fits squarely into what AmyriAD was built to do,” said Ranga Krishnan, MD, Chair of the Board at AmyriAD. “We are a cognition company, and this acquisition allows us to deepen our commitment to developing life-changing therapies for patients with complex neurological needs.”
Recognify Life Sciences appears poised to hand over the reins with confidence. Matthew Pando, PhD, President and CEO of Recognify, noted that AmyriAD’s specialized focus and experienced leadership team make them the ideal successor to shepherd the development of inidascamine. “AmyriAD’s singular focus on cognition and experienced CNS team make it the right owner to take inidascamine forward,” Pando stated.
The clinical foundation for the acquisition is substantial. To date, RL-007 has undergone evaluation in approximately 500 subjects, including a recent Phase IIb study. The drug has maintained a consistent profile regarding safety and tolerability, notably absent of common CNS side effects such as sedation, weight gain, or extrapyramidal symptoms.
While the companies have opted not to disclose the financial terms of the transaction, the acquisition serves as a clear signal of the intensifying interest in cognitive health innovation. As AmyriAD integrates these new clinical assets, the industry will be watching closely to see how this bolstered pipeline advances in the competitive race to treat cognitive decline and psychiatric impairment. This strategic expansion is part of a broader trend of targeted mergers and acquisitions within the pharmaceutical industry as firms seek to secure promising, late-stage neuroscience assets.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
